InvestSMART

ResMed Inc. (ASX: RMD) - Share Price

Current share price for RMD : $27.750 0.03 (0.11%)+

ResMed Inc (RMD), an ASX-listed company, works to increase awareness of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company provides diagnoses and develops treatments for these conditions for people worldwide.

RMD General Information +

ASX Code RMD
Website http://www.resmed.com
Industry/Sector Health Care Equipment
Market Cap ($M) 15,849
RMD Share Price $27.750
Day High $28.050
Day Low $27.640
Last Close $27.720
RMD Share Price Movement $0.03 ( 0.11% )
Prices as at 16:40, 15 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

ResMed Inc. (RMD) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
Result 5.82¢ 0% 13 May 2026 18 Jun 2026 - - -
Result 5.92¢ 0% 11 Feb 2026 19 Mar 2026 - - -
Result 6.43¢ 0% 12 Nov 2025 18 Dec 2025 - - -

See all dividends from ResMed Inc. (RMD) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

ResMed Inc. (RMD) price-sensitive announcements

RMD - Dividend/Distribution - RMD
ResMed Inc. announced a new dividend distribution for its Chess Depositary Instruments (CD
ResMed Inc. (RMD)
1 May 2026 | 8:19 AM
RMD - Resmed Announces Results for the Third Quarter of FY2026
ResMed Inc. announced their financial results for the third quarter of fiscal year 2026, r
ResMed Inc. (RMD)
1 May 2026 | 8:19 AM
RMD - Form 10-Q for the Quarter Ended December 31, 2025
ResMed Inc.'s Form 10-Q for the quarter ended December 31, 2025, reveals significant finan
ResMed Inc. (RMD)
2 Feb 2026 | 8:15 AM
RMD - Resmed Announces Results for the Second Quarter of FY2026
ResMed Inc. announced its financial results for the second quarter of fiscal year 2026, en
ResMed Inc. (RMD)
30 Jan 2026 | 8:26 AM

ResMed Inc. (RMD) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
ResMed Inc. (RMD)
CDI 10:1 FOREIGN EXEMPT NYSE
Health Care $15,850 Statement of changes in beneficial ownership 10 Jun 2026 8:23AM $28.000 $27.750 fallen by 0.89%
ResMed Inc. (RMD)
CDI 10:1 FOREIGN EXEMPT NYSE
Health Care $15,850 Statement of changes in beneficial ownership 4 Jun 2026 8:21AM $25.840 $27.750 risen by 7.39%
ResMed Inc. (RMD)
CDI 10:1 FOREIGN EXEMPT NYSE
Health Care $15,850 Statement of CDIs on issue - RMD 4 Jun 2026 8:21AM $25.840 $27.750 risen by 7.39%
ResMed Inc. (RMD)
CDI 10:1 FOREIGN EXEMPT NYSE
Health Care $15,850 Form SD 27 May 2026 8:25AM $29.250 $27.750 fallen by 5.13%
ResMed Inc. (RMD)
CDI 10:1 FOREIGN EXEMPT NYSE
Health Care $15,850 Update - Dividend/Distribution - RMD 18 May 2026 8:13AM $28.330 $27.750 fallen by 2.05%
ResMed Inc. (RMD)
CDI 10:1 FOREIGN EXEMPT NYSE
Health Care $15,850 4 Statement of changes in beneficial ownership 12 May 2026 8:21AM $28.620 $27.750 fallen by 3.04%

RMD Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026F $2,235.46 $151.45 10.20% 25.03 44.61 1.18% 0.0%
2025F $2,028.91 $137.46 16.70% 27.58 34.38 0.91% 0.0%
2024A $1,737.52 $117.75 23.10% 23.39 30.04 1.09% 0.0%

RMD Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 F 2026 F 2024 A 2025 F 2026 F 2024 A 2025 F 2026 F
Cochlear Limited (COH) $6,729M 0.0171 -0.1883 0.0862 17.1933 21.1817 19.5015 4.18% 3.37% 3.60%
Fisher & Paykel Healthcare Corporation Limited (FPH) $18,658M 0.1388 0.1347 0.1883 48.0417 42.3374 35.6286 1.36% 1.46% 1.65%
ResMed Inc. (RMD) $15,976M 0.3087 9.7634 0.0805 192.3659 17.8722 16.5405 1.20% 1.26% 1.32%

RMD Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.45 18.50 4.45 0.08
Market 0.58 17.20 1.57 1.05
Sector 0.60 21.10 1.57 3.14

RMD Directors

Name Position Start Date
Mr Michael J Farrell Chief Executive Officer, Executive Director 1 Mar 2013
Mr Ronald R Taylor Non-Executive Director 25 Jan 2005
Ms Carol Burt Non-Executive Director 11 Aug 2014
Ms Karen Ruth Drexler Non-Executive Director 17 Nov 2017
Mr Jan De Witte Non-Executive Director 16 May 2019
Ms Harjit Gill Non-Executive Director 15 Nov 2018
Dr John Hernandez Non-Executive Director 19 Nov 2021
Dr Desney Tan Non-Executive Director 19 Nov 2021
Mr Christopher DelOrefice Non-Executive Director 19 Aug 2024
Ms Nicole Mowad Nassar Non-Executive Director 15 Aug 2025
Dr Peter Craig Farrell Non-Executive Director, Non-Executive Chairman 1 Jul 2002

ResMed Inc. (RMD) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
2 Jul 2024 ROBERTS, Christopher Issued Options 12,000 $50.950 $611,400.000
19 Aug 2011 FARRELL, Peter Sell Direct Shares 200,000 $0.000
17 Aug 2011 FARRELL, Peter Issued Related Securities 28,571 $0.000

See all changes in directors' interest & trades for ResMed Inc. (RMD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RMD Management

Name Position
Brett A Sandercock Chief Financial Officer, (Principal Financial Officer and Principal Accounting Officer)

RMD Calendar of Events

Date Event
10 August 2026 Report (Annual)
18 June 2026 Div Pay Date

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.